By engineering immune cells directly within the patient’s body, EsoBiotec is eliminating the barriers of traditional cell therapies and unlocking new possibilities for oncology and immune-mediated diseases.

BOSTON, March 18, 2025: Signal12, a clinical-stage ophthalmic pharmaceutical company has announced the...